Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Atb Cap Markets lowered their FY2024 earnings estimates for shares of Bradmer Pharmaceuticals in a report issued on Sunday, January 26th. Atb Cap Markets analyst M. Toner now anticipates that the company will earn $3.01 per share for the year, down from their prior forecast of $3.63. Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2025 earnings at $1.51 EPS.
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported C($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of C($0.52) by C$0.34.
Bradmer Pharmaceuticals Stock Performance
See Also
- Five stocks we like better than Bradmer Pharmaceuticals
- What Investors Need to Know to Beat the Market
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- How to Invest in Biotech Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- What is Short Interest? How to Use It
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
